PARP inhibitor (olaparib) dramaticalyl extends progression free survival in 1L Maintenance BRCAm ovarian cancer data. Hazard ratio = 0.30. : r/medicine
Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy - European Journal of Cancer
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial - The Lancet Oncology
Study 19: final overall survival in all patients and according to BRCAm... | Download Scientific Diagram
3 Charts | Olaparib: A New Hope for BRCA Patients with Ovarian Cancer
Use of PARP inhibitors in ovarian cancer | Cancer World Archive
SOLO-1 Phase 3 Trial Demonstrates LYNPARZA® (olaparib) Maintenance Therapy Cut the Risk of Disease Progression or Death by 70 Percent in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer | Business Wire
SOLO-2: Overall Survival Data on Olaparib for Relapsed, BRCA-Mutated Ovarian Cancer
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer - Annals of Oncology
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial - The Lancet Oncology
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial - Gynecologic Oncology
PARP inhibitors in ovarian cancer - Cancer Treatment Reviews
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial - The Lancet Oncology
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian... | Download Scientific Diagram
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer - Annals of Oncology
Overall Survival Benefit is Seen with Olaparib in Patients with Ovarian Cancer and TP53 Disruptive Mutation Status | ESMO
Efficacy of LYNPARZA® (olaparib) from Study 19
Olaparib for Metastatic Breast Cancer | NEJM Resident 360 <meta property="twitter:image" content="https://resident360files.nejm.org/image/upload/c_fit,f_auto,h_120,w_120/v1538599218/u8buf4o8mgdxgmfcczjk.png" /> <meta property="og:image" content="https ...
Lynparza extended survival of ovarian cancer patients' < Pharma < 기사본문 - KBR
SOLO-1 Phase III trial demonstrates Lynparza maintenance therapy cut risk of disease progression or death by 70% in patients with newly-diagnosed, advanced BRCA-mutated ovarian cancer
Study 19: final overall survival in all patients and according to BRCAm... | Download Scientific Diagram
Use of PARP inhibitors in ovarian cancer | Cancer World Archive
Olaparib Maintenance Therapy Delays Ovarian Cancer Progression - NCI
18 Efficacy of maintenance olaparib plus bevacizumab by biomarker status in clinical higher- and lower-risk patients with newly diagnosed, advanced ovarian cancer in the PAOLA-1 trial | International Journal of Gynecologic Cancer
Progression-free survival (PFS) and overall survival (OS) following... | Download Scientific Diagram
